Approximately half of all AML adult patients lack clonal chromosome aberrations at diagnosis, and although this group has an intermediate prognosis, only 40% are long-term survivors. Therefore there is a clear need for specific molecular markers to improve prognosis, prediction of relapse and follow-up of AML patients.

Recent studies have shown that high BAALC expression predicts an adverse prognosis and may define an important risk factor in AML patients with normal karyotype but also that high BAALC expression in conjunction with FLT3 mutation status successfully identifies high-risk patients within the heterogeneous group of cytogenetically normal AML patients.

High BAALC expression is established as one of the most important independent risk factors associated with resistant disease, a high cumulative incidence of relapse, and reduced survival.

About BAALC and AML...

• High BAALC expression predicts an adverse prognosis in AML normal karyotype patients
• BAALC over-expression can be used in patients lacking a leukemia-specific marker
• High BAALC expression signs a resistant disease and reduced survival

See relevant publications

Ipsogen ProfileQuant® kits are unique quantitative molecular kits aiming at standardizing, detecting and quantifying profile gene transcripts in human cells.

ProfileQuant® Kit key points

Laboratory advantages

• Use peripheral blood specimen
• Quick test less than 3-hour turn-around time
• Sensitive quantitative measurement of the gene transcript

• 24 to 30 patient samples in duplicate
• Results in normalized copy numbers (NCN)
• Facilities and QMS compliant with ISO 13485 : 2003
• Multiplatform compatibility
• Standardized RQ-PCR procedures